A Therapy for Improving Symptoms in Patients With Acute Exacerbations of COPD by Hydrogen-Oxygen Generator With Neburlizer.
A Therapy for Improving Symptoms in Patients With Acute Exacerbations of COPD by Hydrogen-Oxygen Generator With Neburlizer.
The purpose for this study is to determine safety and effectiveness of the oxyhydrogen
 generator with nebulizer through a therapy for improving symptoms in patients with acute
 exacerbations of copd.
In this study, patients with acute exacerbations of copd who were included in both treatment
 and control groups, administered randomly oxyhydrogen generator with nebulizer (treatment
 group) or oxygen Nebulizer Machine (control group for the therapy. The therapeutic outcomes
 in both treatment and control groups are analyzed and evaluated to verify safety and
 effectiveness of the test product. This study is a multi-center, randomized, double-blind
 study. The trial lasted for about 10 days. The curative effect was observed for subjects in
 the First, the second, the third, the fourth, the fifth, the sixth, the seventh day,
 respectively as the observing time point. Total patients which are planned to be included are
 108 cases, where, 54 cases in the treatment group and control group respectively are
 distributed in 10 clinical hospitals
Inclusion Criteria:

 1. meet the diagnostic criteria of chronic obstructive pulmonary disease (COPD)[1] : In
 the examination of pulmonary function, after inhalation of bronchodilator, the volume
 of forced air in one second accounted for 70% of forced vital capacity (FEV1 / FVC%) ,
 fev180% ;

 2. meet the diagnostic criteria of acute exacerbation of chronic obstructive pulmonary
 disease (AECOPD)[2] : compared with the stable phase, the patient's condition has
 continued to deteriorate, more than the normal changes in the daytime, that is,
 patients with chronic obstructive pulmonary disease foundation for acute onset, need
 to adjust the routine medication. There are at least 2 of the following 3 items in the
 continuous deterioration of clinical symptoms: 1 aggravation of shortness of breath; 2
 increase of Sputum Volume; 3 purulent sputum; or at least 1 of the above 3 symptoms,
 but one of the other 5 indicators should be added, 1 fever; 2 increased respiratory
 frequency and heart rate by 20% compared with the baseline; 3 aggravated cough; 4
 Pharyngodynia and runny in the last 5 days; 5 increased wheezing;

 3. the age is over 40 years old and has the normal independent judgment ability patient,
 the male and the female are not limited;

 4. AECOPD patients requiring in-patient Care;

 5. patients with BCSS score ≥6 at the time of admission;

 6. patients who volunteer for the trial and sign an informed consent form.

 Exclusion Criteria:

 1. screening period of intravenous or oral administration of more than 80 mg / day of
 methylprednisolone or equivalent dose of other hormones or serious need for continuous
 non-invasive ventilation patients;

 2. having a significant disease other than COPD, which, according to the
 researchers'judgement, would put the participants at risk for participating in the
 study or have an impact on the results of the study and the participants'ability to
 participate in the study;

 3. other respiratory diseases: subjects with other active pulmonary diseases, such as
 active tuberculosis, lung cancer, bronchiectasis disease (CT showed repeated acute
 exacerbations of bronchiectasis disease) , sarcoidosis, idiopathic interstitial
 pulmonary fibrosis (IPF) , primary pulmonary hypertension, uncontrolled Sleep apnea
 (i.e. , according to the researchers, the severity of the disease would influence the
 study) ;

 4. Lung Rehabilitation: Participants in the Lung Rehabilitation Program during the study
 period;

 5. a history of severe heart disease such as acute myocardial infarction, congestive
 heart failure (NYHA Class III and above) , Severe Arrhythmia and other acute heart
 disease;

 6. serious primary diseases of important organs and systems, such as acute stroke,
 hypertension above moderate after treatment, active gastric ulcer, diabetes Mellitus
 (serious complication) , malignant tumor, etc.

 7. confirmed and suspected cases of lung cancer;

 8. a history of one or more lobectomies;

 9. limited understanding and poor compliance;

 10. lack of or restricted legal capacity;

 11. those who have participated in clinical trials of other drugs or medical devices
 within 30 days prior to screening but have not reached the end point of the trial;

 12. pregnant, lactating women and women of childbearing age who do not agree to effective
 contraceptive measures during the study period;

 13. Persons with mental or physical disabilities;

 14. a suspected or confirmed history of alcohol or Drug Abuse;

 15. those who are known to be intolerant to inhalation therapy;

 16. AST, ALT were 3 times higher than the normal upper limit, creatinine ≥176.8 MMOL / l;

 17. shock or other Hemodynamics instability;

 18. people with active Hepatitis A, hepatitis B, HIV, tuberculosis, and Infectious Disease
 Connective Tissue Disease;

 19. intravenous hormone therapy for more than 5 days after an acute episode;

 20. non expectorant antioxidants, including high doses of vitamin C and Vitamin E;

 21. the researcher did not consider it appropriate to participate in this study.